目的 探讨百令胶囊联合环磷酰胺和醋酸泼尼松治疗肾病综合征的临床疗效。方法 选取2015年3月—2016年3月在荆州市中心医院接受治疗的80例肾病综合征患者，根据治疗方案的差别分为对照组（40例）和治疗组（40例）。两组患者均给予降压、利尿、降血脂等常规治疗。对照组静脉注射注射用环磷酰胺，10 mg/kg加入250 mL生理盐水，1次/月；同时口服醋酸泼尼松片，起始剂量为40 mg/d，尿蛋白转阴后维持剂量为10 mg/d。治疗组在对照组基础上口服百令胶囊，5粒/次，3次/d。两组患者均连续治疗2个月。观察两组的临床疗效，同时比较两组治疗前后血肌酐（Scr）、血尿素氮（BUN）、24 h尿蛋白排泄率（UPE）、总胆固醇（TC）、三酰甘油（TG）、低密度脂蛋白（LDL-C）、高密度脂蛋白（HDL-C）、白细胞介素-4（IL-4）、肿瘤坏死因子-α（TNF-α）、人11去氢血栓烷B2（11-DH-TXB2）和高迁移率族蛋白B1（HMGB1）的变化情况。结果 治疗后，对照组和治疗组总有效率分别为80.00%、95.00%，两组比较差异有统计学意义（P<0.05）。治疗后，两组患者Scr、BUN、24 h UPE、TC、TG、LDL-C明显降低，HDL-C显著升高，同组治疗前后差异有统计学意义（P<0.05），且治疗组降低的更显著（P<0.05）。治疗后，两组患者IL-4、TNF-α、11-DH-TXB2和HMGB1水平均较同组治疗前降低，且治疗组降低的更显著（P<0.05）。结论 百令胶囊联合环磷酰胺和醋酸泼尼松治疗肾病综合征疗效显著，可明显改善患者肾功能，减轻炎性反应，具有一定的临床应用推广价值。

Objective To explore clinical efficacies of Corbrin Capsules combined with cyclophosphamide and prednisone acetate in treatment of nephrotic syndrome. Methods Patients (80 cases) with nephrotic syndrome in Jinzhou Central Hospital from March 2015 to March 2016 were divided into control group (40 cases) and treatment group (40 cases) according to the different treatments. All patients were given conventional basic treatment with anti-hypertension, diuresis, lipid lowering, etc. The patients in the control group were iv administered with Cyclophosphamide for injection, 10 mg/kg added into 250 mL normal saline, once a month; And they were po administered with Prednisone Acetate Tablets followed by an initial dose of 40 mg/d, then the maintenance dose was 10 mg/d after urinary protein turning negative. The patients in the treatment group were po administered with Corbrin Capsules on the basis of the control group, 5 grains/time, three times daily. The patients in two groups were treated for 2 months. After treatment, clinical efficacies were evaluated. And Scr, BUN, 24 h UPE, TC, TG, LDL-C, HDL-C, IL-4, TNF-α, 11-DH-TXB2, and HMGB1 in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 80.00% and 95.00%, respectively, and there were differences between two groups (P<0.05). After treatment, Scr, BUN, 24 h UPE, TC, TG, and LDL-C in two groups were obviously decreased (P<0.05), and HDL-C was significantly increased, and the difference was statistically significant in the same group (P<0.05). These changes of blood lipid levels in the treatment group were more significantly (P<0.05). After treatment, the levels of IL-4, TNF-α, 11-DH-TXB2, and HMGB1 in the two groups were significantly reduced (P<0.05), and these observational indexes in the treatment group were lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Corbrin Capsules combined with cyclophosphamide and prednisone acetate in treatment of nephrotic syndrome has a significant clinical efficacy, can improve the renal function, and relieve the inflammatory reaction, which has a certain clinical application value.